AstraZeneca Hopes To Save FluMist In US With Foreign Data
This article was originally published in The Pink Sheet Daily
After a CDC advisory committee recommends against the nasal flu vaccine's use in any setting, sponsor AstraZeneca looks to reconcile its effectiveness results with government findings.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.